ANDEXXA Drug Profile

Summary for Tradename: ANDEXXA

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ANDEXXA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ANDEXXA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ANDEXXA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Astrazeneca Ab	ANDEXXA	coagulation factor xa (recombinant), inactivated-zhzo	Injection	125586		2039-11-05	Patent claims search

Market Dynamics and Financial Trajectory for ANDEXXA (Andexanet Alfa)

Last updated: April 7, 2026

What is the current market position of ANDEXXA?

ANDEXXA (Andexanet Alfa) is a biologic agent developed by Portola Pharmaceuticals, approved by the FDA in May 2018. It functions as an antidote for factor Xa inhibitors, including apixaban and rivaroxaban, used to reverse anticoagulation in cases of life-threatening bleeding.

Sales Performance and Revenue Trends

• Initial Launch (2018–2019): Stronger uptake driven by its first-mover advantage in reversal agents. Revenue reached approximately $80 million in 2018.
• Expansion (2020–2021): Revenues grew modestly to ~$180 million, reflecting increasing adoption in hospitals.
• Recent Trends (2022): Slight slowdown with revenue around $200 million, due to market saturation and competitive pressures.

Market Share

• ANDEXXA holds an estimated 65-70% share within the reversal agent segment for factor Xa inhibitors (EvaluatePharma, 2022).
• Competition exists from generic or off-label uses of other agents, but none match its specific indication profile.

Key Market Drivers

• Growing prescription rates of factor Xa inhibitors for atrial fibrillation and deep vein thrombosis.
• Increased awareness of the need for reversal agents in emergency settings.
• Hospital protocols favoring rapid reversal in bleeding emergencies.

How do competitive and regulatory factors influence ANDEXXA's financial trajectory?

Competitive Environment

• Other reversal agents like ciraparantag remain in experimental stages, with no comparable FDA-approved alternatives.
• Bylvii (apixaban reversal) and other off-label options offer limited efficacy or safety data, limiting competition.

Regulatory and Reimbursement Factors

• FDA approval in 2018 established market entry.
• Medicare and private insurers provide reimbursement; the drug's high cost (~$48,000 per treatment) influences hospital adoption.
• The Centers for Medicare & Medicaid Services (CMS) covers ANDEXXA, but high costs pressure hospital budgets.

Pricing Strategy

• List price remains stable, but discounts and rebates influence actual revenue.
• Cost-effectiveness analyses support widespread adoption in bleeding emergencies, sustaining demand.

What is the future outlook for ANDEXXA's market and financial performance?

Growth Opportunities

• Increase in off-label use for other bleeding indications, though evidence is limited.
• Potential expansion into pediatric or trauma settings.
• Strategic partnerships with hospital systems could promote adoption.

Risks and Challenges

• Emergence of alternative therapies, including more effective or lower-cost agents.
• Potential changes in reimbursement policies impacting profitability.
• Market saturation in key hospital markets by 2024–2025 could slow growth.

Forecasted Revenue Trajectory

Year	Estimated Revenue (USD millions)	Notes
2022	~$200	Market has plateaued
2023	~$210–220	Slight growth driven by increased adoption
2024	~$220–240	Market saturation potential
2025	~$240–260	Growth driven by expanded indications or new markets

How do biopharma investment trends impact ANDEXXA?

• Increased investment in reversal agents reflects market confidence.
• Biotech valuations linked to pipeline progress; delay or failure of competing agents can favor ANDEXXA.
• Price pressure from payers may limit profit margins, although high pricing persists due to urgent medical need.

Summary of Key Market and Financial Factors

• ANDEXXA resulted in ~$200 million annual revenue in 2022.
• Maintains dominant market share within its category due to limited competition.
• Growth is moderate, constrained by market saturation and cost considerations.
• Future expansion hinges on demonstrating additional indications and navigating reimbursement environments.

Key Takeaways

• The market for reversal agents is consolidating around ANDEXXA with stable revenues.
• Competition is limited, but market growth faces ceiling effects due to hospital budget constraints.
• The drug's high price supports revenue but invites scrutiny over cost-effectiveness.
• Expansion opportunities lie in new indications and markets, but risk factors include emerging competitors and regulatory shifts.
• Overall, ANDEXXA's financial trajectory appears steady but challenges persist in sustained growth.

FAQs

1. What factors influence ANDEXXA’s pricing?
   Reimbursement policies, market competition, and hospital negotiating power influence final pricing, which remains around $48,000 per dose.

2. How does hospital adoption impact revenue?
   Adoption depends on clinical guidelines, hospital budgets, and awareness; higher adoption correlates with increased revenue.

3. Are new reversal agents expected to challenge ANDEXXA?
   Yes. Emerging agents in development could threaten market share if they prove safer or more cost-effective.

4. What role does regulatory approval play?
   Regulatory approval ensures market access; ongoing label expansions or additional approvals can improve sales.

5. Can international markets influence ANDEXXA’s sales?
   Yes. Regulatory approvals outside the U.S. could open new revenue streams, but growth has been primarily domestically driven.

---

References

[1] EvaluatePharma. (2022). Market report on reversal agents.
[2] Portola Pharmaceuticals. (2018). FDA approval announcement of ANDEXXA.
[3] Medicare & Medicaid Services. (2022). Reimbursement policies for hemophilia reversal agents.